IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.

Slides:



Advertisements
Similar presentations
Weight and Health Susan Fullmer, PhD, RD, CD Associate Teaching Professor Nutrition, Dietetics, and Food Science Brigham Young University.
Advertisements

DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
Sex Differences in Overweight & Obesity.
Adiposity in CVD. Role of adipose tissue in atherogenesis Adapted from de Luca C, Olefsky JM. Nat Med. 2006;12:41-2. Lau DCW et al. Am J Physiol Heart.
Therapy of Type 2 Diabetes Mellitus: UPDATE
METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,
METABOLIC Syndrome: a Global Perspective
Obesity, Metabolic Syndrome and Diabetes in Hispanics: implications on Cardiovascular Disease 2011 Eduardo de Marchena M.D., F.A.C.C., F.A.C.P. Professor.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
cardio protection: Focus on
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stanley Schwartz.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes Stanley Schwartz.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.
Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.
Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Contemporary Management of Cardiometabolic Risk. A continuing epidemic: 2 of 3 US adults are overweight or obese National Health and Nutrition Examination.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 4 Stan Schwartz MD, FACP, FACE.
A Diabetes Outcome Progression Trial
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Diagnosing Diabetes In Adults– Type 1, LADA, or Type 2? Stanley Schwartz MD, FACE, FACP Affiliate Main Line Health Emeritus, Clinical Assoc. Prof. of Medicine.
Therapy of Type 2 Diabetes Mellitus: UPDATE
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & Early DM Part 5 Stan Schwartz MD, FACP, FACE.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Practical Implementation as a Discussion with the Patient Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria Stan Schwartz.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.
Current Classification of DM Update on Diabetes Classification Celeste C. Thomas, MD, MSa,*, Louis H. Philipson, MD, PhD,Med Clin N Am 99 (2015) 1–16.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
A Process Of Precision Medicine- Matching Right Drug to Right Patient.
CV Risk of SU and Insulin
The β-Cell Centric Classification of DM
A Process Of Precision Medicine- Matching Right Drug to Right Patient
Endocrine Block 1 Lecture Dr. Usman Ghani
Targets for Therapies/ New Guidelines
By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology
Part 5 Stan Schwartz MD, FACP, FACE Private Practice, Ardmore
Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.
Endocrine Block 1 Lecture Dr. Usman Ghani
Pushback What about ‘pure’ Insulin Resistance Syndromes?
Inflammation/Immune Issues
Choice of Therapy MYTH: “Most Patients with ‘T2DM’ will eventually
Simplistic Inflammatory and Non-Inflammatory Effects of Insulin Resistance on B-Cell Function IAPP boosts islet macrophage IL-1 in type 2 diabetes : Nature.
Diet, Obesity, and Chronic Disease
Presentation transcript:

IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor of Medicine, U of Pa. Part 4

The Adipocytokine Syndrome: A New Model for Insulin Resistance and ß- Cell Dysfunction Muscle Pancreas Liver Brain Visceral fat cells FFA, TNF  Leptin Leptin Sns FFA, TNF  IL-6 Angiotensinogen, PAI-1 Adiponectin CRP, PAI-1 Atherothrombosis FFA, TNF  Adiponectin Artery FFA Resistin, TNF  ObesityIRDiabetesASVD

“Sick” Dysfunctional, Adiposopathic Fat Cell ADIPOCYTE ASP & Adipsin FFA TNF  MIFIL-6LeptinPAI-1 Resistin Angioten- sinogen Adiponectin Bays H, Mandarino L, DeFronzo RA. J Clin Endocrinol Metab. 2004;89:

Overweight Overweight and Obesity Increase the Risk of CV Disease Mortality Data are from 1 million men and women (average age, 57 years) followed for 16 years who never smoked and had no history of disease at enrollment. Calle EE, et al. N Engl J Med. 1999;341: Normal weightObese Relative Risk of Cardiovascular Disease Mortality > >40 BMI, kg/m 2 Women Men

Weight Loss Reduces Cardiometabolic Risk Factors in Patients With Type 2 Diabetes Δ A1C (%) * Δ HDL Cholesterol (mg/dL) * Intensified Lifestyle Intervention, 8.6% Weight Loss Diabetes Support and Education, 0.7% Weight Loss Randomized, controlled trial; n = 5145; Patients with type 2 diabetes, age >18 y; Mean ± SE Intensified lifestyle intervention (n = 2496) vs diabetes support and education (n = 2463) therapy; *P<0.001 between groups Look AHEAD Research Group. Diabetes Care. 2007;30: Δ Triglycerides (mg/dL) * Δ Blood Pressure (mm Hg) * * SystolicDiastolic

Implications for Therapy  Treat Central Mechanisms IR  Treat Peripheral IR- fat, liver, muscle  Treat Inflammation  Treat Biome

Gene(s) Environment Amylin B-Cell function/ mass GLP-1 resistance, incretin effect Insulin resistance Appetite SCN ( dopa surge) BRAIN- insulin glucagon cells ‘complain’ not getting enough glucose Ppg--- HYPERGLYCEMIA lipotoxicity Up-regulates SGLT-2 glucotoxicity Gene/ envir inter- action!! Colon biome B-Cell-Centric Construct for Pathogenesis of All Diabetes-Implications for RX - EGREGIOUS ELEVEN Inflammation Kidney Fat Liver Muscle Stomach Fast emptying INSURES its GETTING ENOUGH GLUCOSE TO WORK!! *

Yumi Imai1, Anca D. Dobrian2, Margaret A. Morris1,3, and Jerry L. NadlerIslet inflammation: a unifying target for diabetes treatment? Trends in Endocrinology and Metabolism 2013:1- 10 ; Barbara Brooks-Worrell, Radhika Narla, and Jerry P. Palmer Biomarkers and immune-modulating therapies for Type 2 diabetes Trends in Immunology November 2012, Vol. 33, No. 11 New β-Cell Centric Construct: Implications Inflammation Issues Initiators of inflammation IAPP Glucose Saturated FFA IL-1β Cytokines (TNFα, IL-6, IL-12, IL-1 α, IL-8) 12-HETE

Yumi Imai1, Anca D. Dobrian2, Margaret A. Morris1,3, and Jerry L. Nadler,Islet inflammation: a unifying target for diabetes treatment? Trends in Endocrinology and Metabolism 2013:1- 10 ; Barbara Brooks-Worrell, Radhika Narla, and Jerry P. Palmer Biomarkers and immune-modulating therapies for Type 2 diabetes Trends in Immunology November 2012, Vol. 33, No. 11 New β-Cell Centric Construct: Implications Inflammation Issues Downstream Effects

Implications for Therapy  Treat Central Mechanisms IR  Treat Peripheral IR- fat, liver, muscle  Treat Inflammation  Treat Biome

Metabolic Derangement, Insulin Resistance Associated with Microbiome Lipopolysaccharides LPS Fasting-induced adipocyte factor